Your browser doesn't support javascript.
loading
Enhancing Tumor Targeting Efficiency of Radiolabeled Uridine (via) Incorporation into Nanocubosomal Dispersions.
Sayed, Manal M; El-Sabagh, Hanan A; Al-Mahallawi, Abdulaziz M; Abd El-Halim, El-Sayed; Amin, Abeer M; AbdEl-Bary, Ahmed.
Afiliación
  • Sayed MM; Department of Labeled Compounds, Hot Labs Center, Egyptian Atomic Energy Authority, Cairo, Egypt.
  • El-Sabagh HA; Department of Labeled Compounds, Hot Labs Center, Egyptian Atomic Energy Authority, Cairo, Egypt.
  • Al-Mahallawi AM; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
  • Abd El-Halim ES; Department of Pharmaceutics, Faculty of Pharmacy, October University for Modern Science and Arts (MSA), Giza, Egypt.
  • Amin AM; Department of Labeled Compounds, Hot Labs Center, Egyptian Atomic Energy Authority, Cairo, Egypt.
  • AbdEl-Bary A; Department of Labeled Compounds, Hot Labs Center, Egyptian Atomic Energy Authority, Cairo, Egypt.
Cancer Biother Radiopharm ; 35(3): 167-176, 2020 Apr.
Article en En | MEDLINE | ID: mdl-32074460
Background: Several nanosystems are currently being utilized to enhance the targeting efficiency of several cancer chemotherapeutic agents. This study was designed to improve tumor accumulation of iodine-125 (125I)-uridine via incorporation into a nanocubosomal preparation. Materials and Methods: Nanocubosomes were prepared with the aid of Glycerol mono-oleate and Pluronic F127. Each prepared nanocubosomal preparation was adequately characterized by testing their particle size, polydispersity index (PDI), ζ potential (ZP), and transmission electron microscopy. The radiolabeling of uridine with 125I was attempted using several oxidizing agents to achieve a high radiochemical yield, and the factors affecting the reaction yield were studied in detail. A comparative biodistribution study of free 125I-uridine and 125I-uridine loaded nanocubosomes was performed in normal and tumor bearing mice. The biodistribution was evaluated by intravenous injection of the sterile test solution, and animals were anesthetized and dissected at different time intervals postinjection (p.i.). Results: 125I-uridine was obtained in a high radiochemical yield (92.5% ± 0.8%). Afterward, 125I uridine was incorporated in a selected nanocubosome formulation, which showed nanosized cubic particles (178.6 ± 0.90 nm) with PDI (0.301 ± 0.04) and a ZP (34.35 ± 0.4). The biodistribution studies revealed that 125I-uridine nanocubosomes showed higher tumor localization (3.1 ± 0.4%IA/g at 2 h p.i. and a tumor/muscle ratio of 6.2) compared with the free 125I-uridine (2.7% ± 0.4%IA/g at 2 h p.i. and a tumor/muscle ratio of 3.3). Conclusion: The results of this study confirmed that 125I-uridine loaded nanocubosome had better efficiency in targeting the tumor site, which makes it an adequate targeting agent for tumor imaging.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Uridina / Portadores de Fármacos / Nanopartículas / Neoplasias Límite: Humans Idioma: En Revista: Cancer Biother Radiopharm Asunto de la revista: FARMACIA / FARMACOLOGIA / NEOPLASIAS / TERAPEUTICA Año: 2020 Tipo del documento: Article País de afiliación: Egipto

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Uridina / Portadores de Fármacos / Nanopartículas / Neoplasias Límite: Humans Idioma: En Revista: Cancer Biother Radiopharm Asunto de la revista: FARMACIA / FARMACOLOGIA / NEOPLASIAS / TERAPEUTICA Año: 2020 Tipo del documento: Article País de afiliación: Egipto
...